Document Detail


Is there an association between the measurement of qualitative HBsAg and virologic response in chronic HBV infection?
MedLine Citation:
PMID:  22481449     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: In the follow up of chronic hepatitis B infection (HBV), a significant correlation between quantitative HBsAg titer measurement and HBV DNA level, and moreover with intrahepatic covalently closed circular DNA was already shown. However, besides their impact on long-term follow up, they are really expensive methods, and not available widespread. We aimed to investigate the utility of qualitative measurement of HBsAg titer in prediction of virologic response at the end of the first year of anti-viral treatment in chronic HBV infection.
MATERIAL AND METHODS: A total of 70 patients receiving anti-viral therapies for chronic HBV infection were included into the study. The patients were evaluated according to Hbe Ag status and response to treatment. The determinations used in the study (biochemical, virologic responses, primary non-response) were accepted as it was described in AASLD.
RESULTS: Qualitative HBsAg titer increased significantly in both HBeAg positive and negative patients (p values 0.002 and < 0.000). Increasing of HBsAg titer in first three months is more dramatic in responder group, however the difference was disappeared at the sixth and twelve moths on follow up. Similarly, a fast increasing in anti-HBe titer in HBeAg negative chronic HBV patients was related with higher response at the end of first year therapy. However, the changings at the 12th month of anti-viral treatment were similar in both responder and non-responder groups.
CONCLUSION: In conclusion, the fast increase in qualitative measurement of HBsAg titer seemed to be a predictor of higher anti-viral medication success in chronic HBV patients. However, this meaningful increasing was disappeared on the follow up, particularly after the six months examination.
Authors:
Akif Altinbas; Bora Aktas; Omer Basar; Osman Yüksel; Fuat Ekiz; Baris Yilmaz; Sahin Coban
Related Documents :
22509189 - Hepatitis b virus genotype g infection in a turkish patient undergoing hemodialysis the...
22297889 - Genotypical diversity of hiv clades and central nervous system impairment.
22782789 - Sexual behavior as a function of stigma and coping with stigma among people with hiv/ai...
8005709 - Urine as an alternative to urethral swabs for the diagnosis of chlamydia trachomatis in...
22803699 - Prevalence of human t-lymphotropic virus type 1 and 2 infection in sweden.
9643159 - Evaluating the laboratory techniques used in the diagnosis of sputum-producing-patients...
23970589 - Testicular and kidney masses in a hiv-infected man.
19824079 - Public health impact of antiviral therapy for hepatitis c in the united states.
2674369 - Epidemiology and transmission of hiv infection in women. considerations for nurse-midwi...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Annals of hepatology     Volume:  11     ISSN:  1665-2681     ISO Abbreviation:  Ann Hepatol     Publication Date:    2012 May-Jun
Date Detail:
Created Date:  2012-04-06     Completed Date:  2012-08-23     Revised Date:  2013-05-16    
Medline Journal Info:
Nlm Unique ID:  101155885     Medline TA:  Ann Hepatol     Country:  Mexico    
Other Details:
Languages:  eng     Pagination:  320-5     Citation Subset:  IM    
Affiliation:
Diskapi Yildirim Beyazit Education and Research Hospital, Gastroenterology Clinic, Ankara, Turkey. drakifa@yahoo.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenine / analogs & derivatives,  pharmacology,  therapeutic use
Adult
Aged
Antiviral Agents / pharmacology,  therapeutic use*
Biological Markers / blood
DNA, Viral / blood*
Drug Resistance, Viral*
Female
Follow-Up Studies
Guanine / analogs & derivatives,  pharmacology,  therapeutic use
Hepatitis B Surface Antigens / blood*
Hepatitis B virus / drug effects,  genetics*
Hepatitis B, Chronic / blood*,  drug therapy*,  immunology
Humans
Interferons / pharmacology,  therapeutic use
Lamivudine / pharmacology,  therapeutic use
Male
Middle Aged
Organophosphonates / pharmacology,  therapeutic use
Predictive Value of Tests
Time Factors
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antiviral Agents; 0/Biological Markers; 0/DNA, Viral; 0/Hepatitis B Surface Antigens; 0/Organophosphonates; 0/entecavir; 107021-12-5/tenofovir; 134678-17-4/Lamivudine; 73-24-5/Adenine; 73-40-5/Guanine; 9008-11-1/Interferons

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Different models in predicting the short-term prognosis of patients with hepatitis B virus-related a...
Next Document:  Hepatitis A vaccination in healthcare personnel.